These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22858211)

  • 21. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
    Mancini M; Sheehan DV; Demyttenaere K; Amore M; Deberdt W; Quail D; Sagman D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):298-309. PubMed ID: 22954893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
    J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early symptom change prediction of remission in depression treatment.
    Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
    Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
    Wade A; Gembert K; Florea I
    Curr Med Res Opin; 2007 Jul; 23(7):1605-14. PubMed ID: 17559755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
    Kornstein SG; Dunner DL; Meyers AL; Whitmyer VG; Mallinckrodt CH; Wohlreich MM; Detke MJ; Hollandbeck MS; Greist JH
    J Clin Psychiatry; 2008 Sep; 69(9):1383-92. PubMed ID: 19193339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
    Raskin J; George T; Granger RE; Hussain N; Zhao GW; Marangell LB
    J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Wang J; Liu X; Mullins CD
    Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.
    Sheehan DV; Chokka PR; Granger RE; Walton RJ; Raskin J; Sagman D
    Hum Psychopharmacol; 2011 Apr; 26(3):242-51. PubMed ID: 21681815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity.
    Wise TN; Wiltse CG; Iosifescu DV; Sheridan M; Xu JY; Raskin J
    Int J Clin Pract; 2007 Aug; 61(8):1283-93. PubMed ID: 17590215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.
    Sheehan DV; Meyers AL; Prakash A; Robinson MJ; Swindle RW; Russell JM; Mallinckrodt CH
    Curr Med Res Opin; 2008 Sep; 24(9):2457-66. PubMed ID: 18662492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
    Signorovitch J; Ramakrishnan K; Ben-Hamadi R; Yu AP; Wu EQ; Dworak H; Erder MH
    Curr Med Res Opin; 2011 Jun; 27(6):1089-96. PubMed ID: 21438794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
    Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attributes of response in depressed patients switched to treatment with duloxetine.
    Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
    Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
    Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.